Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics' stock has experienced significant volatility in the past six months. As of October 24, 2025, the share price had increased by 56.67% over the preceding 12 months. However, on October 27, 2025, the stock plummeted by over 40% following the announcement of a temporary pause in patient dosing and screening for its Phase 3 clinical trials of nexiguran ziclumeran due to a serious adverse event. Earlier in the year, in January 2025, Intellia announced a strategic reorganization that included a net workforce reduction of approximately 27% and the discontinuation of the NTLA-3001 program.

As a clinical-stage biotechnology company without approved commercial products, Intellia Therapeutics, Inc. does not have demand seasonality in the traditional sense. The company's revenue is primarily derived from strategic collaboration agreements and licensing arrangements, which can vary significantly year-over-year.

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing CRISPR-based genome editing treatments. They have both in vivo programs, where CRISPR is administered intravenously, and ex vivo programs, which use engineered human cells. Key product candidates include Lonvo-z for Hereditary Angioedema (HAE), which is in Phase 3 clinical trials and aims to provide lifelong control of HAE attacks with a single dose. Nexiguran Ziclumeran is an investigational CRISPR therapy for Transthyretin (ATTR) Amyloidosis, but patient dosing and screening were temporarily paused in October 2025 due to a serious adverse event. Intellia also has research programs for immuno-oncology/autoimmune diseases and Hemophilia B, and previously had a program for alpha-1 antitrypsin deficiency (NTLA-3001) but discontinued its development in January 2025.

Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States, where its primary research and development activities are based.

Intellia Therapeutics' brand reputation has been influenced by clinical trial progress and corporate decisions. Positive developments, such as the advancement of Lonvo-z and nex-z into late-stage clinical trials, contributed to positive sentiment. However, the temporary pause of Phase 3 clinical trials for nex-z due to a serious adverse event led to a sharp decline in stock price and raised concerns about the safety of its gene-editing therapies. The decision to reduce its workforce by 27% and discontinue certain research programs also reflected a challenging market environment.

Intellia Therapeutics, Inc. has a mix of institutional, retail, and individual investors, with 498 institutional owners holding a total of 120,796,675 shares. Major institutional owners include ARK Investment Management LLC, Vanguard Group Inc, BlackRock, Inc., Morgan Stanley, State Street Corp, Regeneron Pharmaceuticals Inc, and Baker Bros. Advisors Lp. Caribou Therapeutics Holdco LLC is the largest individual shareholder, owning 5.59 million shares, representing 5.40% of the company.